The ALKBH5 Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from Jurkat T lymphocytes, featuring targeted disruption of the ALKBH5 gene. This heterogeneous loss-of-function model avoids clonal artifacts and supports robust analysis of ALKBH5-dependent m6A demethylation. The stable gene disruption provides a reliable tool for studying RNA modification roles in T cell biology and leukemogenesis.
Jurkat cells, derived from acute T cell leukemia, are an immortalized model for T cell signaling and leukemia biology. These suspension cells express relevant T cell markers and signaling pathways, including those influenced by ALKBH5-mediated m6A regulation. Their established use in gene perturbation studies makes them an ideal host for dissecting ALKBH5??s impact on mRNA metabolism and leukemic cell growth.
ALKBH5 is an RNA demethylase that removes m6A from mRNA, counteracting the METTL3/METTL14/WTAP writer complex. Upstream, it is regulated by HIF-1?? under hypoxia and the PI3K/AKT pathway, and transcriptionally controlled by MYC. ALKBH5 demethylation modulates stability and translation of downstream targets such as NANOG, MYC, FOXM1, SOX2, and apoptosis regulators. These m6A marks are read by YTHDF1/2/3 proteins, influencing transcript fate. Consequently, ALKBH5 integrates signaling inputs to govern proliferation, stemness, and stress responses.
In Jurkat cells, ALKBH5 knockout disrupts m6A homeostasis, enabling investigation of its roles in leukemogenesis. The polyclonal pool captures heterogeneous effects, facilitating bulk m6A analyses and identification of robust phenotypes. This model is especially suited for studying ALKBH5-MYC crosstalk and m6A-dependent regulation of T cell activation, apoptosis, and proliferation??processes central to T-cell leukemia.
Applications include MeRIP-seq for m6A profiling, RT-qPCR and Western blotting for target validation, flow cytometry for activation and apoptosis markers, and functional assays such as proliferation and drug sensitivity screens. This polyclonal knockout population supports mechanistic and translational research into m6A demethylation in cancer. For further information, contact Ascent Research.
